DMP logo

Dermapharm Holding SE Stock Price

XTRA:DMP Community·€1.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

DMP Share Price Performance

€34.40
-0.35 (-1.01%)
€34.40
-0.35 (-1.01%)
Price €34.40

DMP Community Narratives

There are no narratives available yet.

Snowflake Analysis

Undervalued with proven track record.

2 Risks
4 Rewards

Dermapharm Holding SE Key Details

€1.2b

Revenue

€419.0m

Cost of Revenue

€770.0m

Gross Profit

€653.9m

Other Expenses

€116.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 31, 2026
2.16
64.76%
9.76%
156.4%
View Full Analysis

About DMP

Founded
1991
Employees
3551
CEO
Hans-Georg Feldmeier
WebsiteView website
ir.dermapharm.de

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

Recent DMP News & Updates

Recent updates

No updates